{
    "ticker": "INVA",
    "name": "Innoviva, Inc.",
    "description": "Innoviva, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat infectious diseases and other serious medical conditions. Founded in 2014, Innoviva leverages its proprietary platform and strategic partnerships to advance a diverse pipeline of product candidates. The company is known for its collaboration with major pharmaceutical companies, particularly in the respiratory therapeutic area, where it has made significant contributions through its partnership with GlaxoSmithKline (GSK) for the development of inhaled antibiotics. Innoviva's mission is to improve the lives of patients suffering from chronic and acute diseases, and it is committed to discovering and delivering transformative therapies that address unmet medical needs. With a strong emphasis on research and development, Innoviva aims to expand its portfolio through innovative drug development strategies and collaborations. The company is headquartered in San Francisco, California, and its focus on patient-centered solutions drives its strategic initiatives and partnerships.",
    "industry": [
        "Biopharmaceuticals",
        "Healthcare"
    ],
    "headquarters": "San Francisco, California, USA",
    "founded": "2014",
    "website": "https://www.innovivainc.com",
    "ceo": "Rebecca Tauber",
    "social_media": {
        "twitter": "https://twitter.com/InnovivaInc",
        "linkedin": "https://www.linkedin.com/company/innoviva-inc"
    },
    "investor_relations": "https://www.innovivainc.com/investors",
    "key_executives": [
        {
            "name": "Rebecca Tauber",
            "position": "CEO"
        },
        {
            "name": "Michael E. Hurst",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Inhaled Antibiotics",
                "Anti-infective Agents"
            ]
        }
    ],
    "seo": {
        "meta_title": "Innoviva, Inc. | Biopharmaceuticals for Infectious Diseases",
        "meta_description": "Explore Innoviva, Inc., a biopharmaceutical company dedicated to developing innovative therapies for infectious diseases and serious medical conditions.",
        "keywords": [
            "Innoviva",
            "Biopharmaceuticals",
            "Infectious Diseases",
            "Healthcare",
            "Therapeutics"
        ]
    },
    "faq": [
        {
            "question": "What does Innoviva, Inc. specialize in?",
            "answer": "Innoviva specializes in the development and commercialization of innovative therapeutics for infectious diseases."
        },
        {
            "question": "Who is the CEO of Innoviva?",
            "answer": "Rebecca Tauber is the CEO of Innoviva, Inc."
        },
        {
            "question": "Where is Innoviva headquartered?",
            "answer": "Innoviva is headquartered in San Francisco, California, USA."
        },
        {
            "question": "What are the main therapeutic areas of Innoviva?",
            "answer": "Innoviva focuses primarily on respiratory therapeutics and anti-infective agents."
        },
        {
            "question": "When was Innoviva founded?",
            "answer": "Innoviva was founded in 2014."
        }
    ],
    "competitors": [
        "GSK",
        "ABBV",
        "VRTX",
        "AMGN"
    ],
    "related_stocks": [
        "PFE",
        "JNJ",
        "MRK",
        "BMY"
    ]
}